Nuvalent, Inc. 4

Insider Michael L. Meyers had all 5,146 Nuvalent Class A shares, 3,444 RSUs, and multiple stock option grants cashed out at the $124.00 per share merger price, leaving him with no remaining holdings.

On July 15, 2026, in connection with the closing of GlaxoSmithKline’s acquisition of Nuvalent, Inc., Michael L. Meyers had all 5,146 shares of Class A Common Stock he held exchanged for cash at the $124.00 per share offer price, and all of his equity awards were cancelled for cash. This included 3,444 time‑based restricted stock units and multiple tranches of stock options with exercise prices of $6.89 (8,361 options), $19.48 (40,000 options), $44.68 (15,000 options), $80.03 (3,789 options), and $75.53 (4,147 options), each converted into the right to receive cash equal to (i) for RSUs, shares multiplied by $124.00, and (ii) for options, shares multiplied by the excess of $124.00 over the applicable exercise price, all subject to withholding. Following these merger-related cash-out transactions, Meyers reported no remaining ownership of Nuvalent Class A Common Stock or derivative securities, as the company became a wholly owned subsidiary of GlaxoSmithKline LLC.

Filing Facts

CIK

1861560

Ticker

NUVL

Form

4

Source Type

fda

Accession

0001193125-26-305095

Alert Tier

6